Roquette Acquires Itacel
Roquette has completed its previously announced acquisition of Itacel, an excipient division of Blanver.
On Sept. 1, 2017, Roquette, a French biopharmaceutical company specializing in plant-based excipients, completed the previously announced acquisition of Itacel. Itacel is an excipient division of Blanver, a Brazilian multinational company specializing in the development, manufacture, and commercialization of raw materials and drugs.
The acquisition is part of a series of investments made by Roquette to position itself globally, according to the company. Financial details of the closing are unpublicized.
Source: Roquette
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Novartis Acquisition of Regulus Therapeutics is Complete
June 25th 2025A key property included in the acquisition is farabursen, an investigational next-generation oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat people with autosomal dominant polycystic kidney disease.
